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Abstract
Amyotrophic Lateral Sclerosis (ALS) is a terminal neurodegenerative disease
with symptoms including limb-onset muscle wasting, difficulties swallowing and
breathing, leading to death. Sporadic ALS occurs in 90% of patients, while 10% of cases
are familial (FALS). Twenty percent of FALS cases are a result of mutation in the
copper-zinc superoxide dismutase (SOD1) gene, leading to the activation of the
mitochondrial apoptosis pathway. Meanwhile, a prominent cause of sporadic ALS is
exposure to neurotoxins, such as β-methylamino-L-alanine (BMAA). BMAA has been
suggested to induce selective motor neuron death, which is observed in ALS patients.
While research has been done to how BMAA may impacts organisms on the cellular
level, not much has been performed on the genetic or epigenetic level. This research
investigates how BMAA and mutations in the SOD1 gene affect the regulation of wellknown neurological genes. Within the year, zebrafish from four different genotypes were
subjected to three different BMAA concentrations, and spinal samples from these fish
were collected. RNA was extracted from these and cDNA was produced from the
resulting RNA. RNA concentrations varied significantly in concentration and purity,
while cDNA concentrations were more pure and higher in concentration. The spinal
samples also displayed that fish exposed to 2.5 µg/L of BMAA had the lowest levels of
actin transcripts, reflected in previous work that these fish would have the shortest motor
neuron axons. These samples can now be used to perform transcriptome analysis to detect
the regulation of neurological genes depending on BMAA concentration and SOD1
mutation.
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Introduction
Amyotrophic Lateral Sclerosis:  
ALS is the fourth most prevalent neurodegenerative disease, following
Alzheimer’s, Pick’s, and Parkinson’s disease.1 Symptoms of ALS typically (70% of
cases) start with limb-onset muscle wasting, and lead to difficulties in swallowing,
respiratory weakness, unclear speech, depression, and eventually death.2 Research
looking into the association with ALS and depression focuses on the prevalence of
depression in ALS patients more often than the biological cause of depression in said
patients3. While one-fifth of patients live up to five to ten years after symptoms begin,
half of all patients diagnosed with ALS die within 30 months of symptom onset.2 There
are no current cures for the disease, although there is one treatment; Riluzole. However, it
only prolongs life for patients for a few months.4 Only between 5-10% of ALS are
familial (FALS)5, indicating that between 90 and 95% of cases are sporadic (SALS). Of
the FALS cases, 20% of them involve mutations in the copper-zinc superoxide dismutase
gene (SOD1).6
SOD1 is an enzyme found in the inner mitochondrial space and the nucleus of
cells. It is a dimer made of two identical constitutively expressed polypeptides, bound by
hydrophobic interactions. Each polypeptide is 153 amino acids long, and dimerization is
stabilized and catalyzed by a zinc and copper ion. Its function is to convert superoxide
into hydrogen peroxide.7,8 SOD1 mutations, have generally been shown to induce a toxicgain of function, rather than a loss of function.9 This toxic gain of function is caused by
the aggregation of mutant SOD1 protein, and binding to B-cell lymphoma (Bcl) proteins
on the outer membrane of mitochondria.10
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Use of zebrafish as an ALS Model:
The zebrafish is a useful model for studying ALS because it develops quickly,
produces numerous offspring multiple times a day, and is more cost effective than other
models such as a mouse or rat. More importantly, the physiology of the zebrafish
neuromuscular system is similar to humans. This neuromuscular system develops rapidly,
and is well characterized.12,13,14,15 . Also, since the zebrafish breeds by laying eggs in
shallow water, its embryos are externally developed, and absorb any toxins placed into
their environment through their derma.16. We use several transgenic zebrafish models in
our experiment. The models are non-transgenic SOD1 zebrafish littermates (nTG-SOD1wt), transgenic wildtype SOD1 zebrafish (SOD1-wt), littermates of mutant SOD1
zebrafish (nTG-SOD1-G93R), and transgenic mutant SOD1 zebrafish (SOD1-G93R).
Models labeled as transgenic overexpress the SOD1 allele they possess.

  β – Methyamino-L-alanine:
β – Methyamino-L-alanine (BMAA) is a non-‐proteogenic amino acid discovered
in high concentrations (627 µg BMAA/g brain tissue) in the brains of the Chamorro
people, native to Guam. This is an approximately fifteen times higher concentration than
that found in brains of people serving as neurological controls (41 µg BMAA/g brain
tissue). This is significant because the Chamorro people had a 100x fold higher rate of
developing ALS than the average population.10 The source of the BMAA for the
Chamorro is cycad seeds. The cycad plants have a symbiotic relationship with
cyanobacteria, which reside in the coralloid roots. The BMAA resulting from the
cyanobacteria accumulates into the seeds.17 The Chamorro people would not only grind

7

cycad seeds into flour, but would also consume animals which eat cycad seeds mainly
flying foxes. Thus, these people can acquire the amino acid through multiple sources of
bioaccumulation.18
BMAA does not only exist in these plants; it has been found in many fresh and
salt water sources, including lakes in the United Kingdom 19and New Hampshire20, and
the Baltic Sea21. People exposed multiple times to cyanobacterial harmful Algal Blooms
(HABs) have between a 10 to 25 times chance of developing ALS than those not near
these events.22 Also, while BMAA is primarily noted in HABs globally, 10 it is also
produced by other organism including diatoms23 and dinoflagellates 24. Fish and shellfish
predate on these organism, providing another avenue for people to be exposed to BMAA
through bioaccumulation10.
There are multiple mechanisms proposed as to how BMAA affects motor
neurons, depending if the amino acid is free floating or incorporated into proteins. When
outside of the cell, free-floating BMAA acts as an agonist for glutamate receptors such as
NMDA and AMPA/kainaite. When introduced to mixed spinal cord culture at 30 µM,
BMAA was shown to induce selective motor neuron death, demonstrating it as a potential
mechanism for ALS development10. There are also suggestions that it can be incorporated
into proteins, which can cause proteins to become misfolded25, and these proteins act as
BMAA reservoirs26. Since BMAA is a fairly well known neurotoxin that is prevalent
worldwide, and has evidence of causing symptoms of ALS, BMAA is the contending
neurotoxin used in this research.
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Experimental Design:
In a previous experiment in the Sher Lab, performed by Samantha Powers
[personal communication], zebrafish with and without the G93R SOD1 mutation were
exposed to different concentrations of BMAA. Then the axons of the motor neurons
located in the lumbar spines of each fish were measured. Fish without the mutation were
observed to have shorter motor neuron axons as the concentration of BMAA exposure
increased. Fish with the mutation and exposed to the BMAA had the shortest axons at 2.5
µg/L BMAA concentration, but demonstrated longer axons at higher and lower BMAA
concentrations, indicating a recovery mechanism existed to compensate for the short
axons. This lead into curiosity about how genes were expressed when the fish had the
mutation, and when they were exposed to different BMAA concentrations at the start of
development.
In past parts of this current experiment, performed by Samamtha Powers, the
seventy-two zebrafish were distributed evenly into the four genotypes of zebrafish, and
were exposed to three different concentrations of BMAA. After six months of living in
non-toxic water, their lumbar spinal cords were extracted, frozen in liquid nitrogen, and
stored at -80°C.27 Half of each sample group (3 fish per genotype per dose) were sent for
proteomic analysis to be performed by Dr. Randall Moon, University of Washington. 28
The remaining spines, in this current research, went through RNA extraction, cDNA
production, and subsequent RNA expression analysis. While this current research was
supposed to continue with microarray analysis of the spinal samples with in this research,
time restraints prevented this from occurring.
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Hypothesis:
It is known that BMAA has detrimental effects on the phenotype of motor
neurons, from selective motor neuron death in cell culture to decreased axon length in
motor neurons. From previous research, phenotypic change was observed in the length of
motor neuron axons, indicating possible changes in the transcriptome and/or the
proteasome. Through the microarray analysis, we wanted to observe the genetic
regulation patterns exhibited in zebrafish when exposed to different concentrations in
BMAA and when they had the SOD1-G93R mutation. Specifically, the genes involved in
neurodevelopment would decrease when exposed to BMAA, and increase in fish with the
G93R mutation when exposed to 5.0 µg/L BMAA.
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Materials and Methods
Spine extraction: Seventy-two zebrafish of four different genotypes (nTG-SOD1-wt,
SOD1-wt, nTG-SOD1-G93R, and SOD-G93R) were exposed to three different doses of
BMAA (0.0, 2.5, and 5.0 ug/L). The fish developed for 188 days, and were euthanized
with Tricane-S (300mg/L) (Western Chemical INC, Ferndale, WA). Each fish was
dissected, and the lumbar region was isolated. Spinal cords were pulled from exposed
column. Individual spines were frozen in liquid nitrogen, and stored at -80°C.27 Half of
the samples were sent for proteomics, while the others were saved for RNA extraction.28

RNA extraction: RNA was individually extracted from 35 zebrafish lumbar spinal cords
using a phenol-chloroform protocol. The frozen spines were homogenized using a frozen
pestle, and TRIzol (800 µL) and 1mg/mL glycogen (200 µL) were added to each sample.
Samples incubated in Phase Lock Gel Tubes (5 Prime, Gaithersburg, MD). Chloroform
was added. Samples were centrifuged at 12000xg for twenty minutes at room
temperature. The resulting pellets were washed twice, with isopropanol and 75% ethanol,
and centrifuged after each wash. Pellets were left to dry, and the RNA were suspended in
15 µL of nuclease-free water. RNA samples were analyzed using a NanoDrop
spectrophotometer (NanoDrop 2000; Thermo Scientific; Rochester, NY).

cDNA production: cDNA was produced in 20 µL reactions using the Applied
Biosystems cDNA Reverse Transcription kit (Applied Biosystems; Carlsbad, CA).
Primers used were a 1:1 ratio of Random primers, which came with the kit, and Oligo-DT
nucleotides (Thermo Scientific, Waltham, MA). The protocol that utilizes the RNase
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inhibitor was followed in the procedure. The amount of RNA added per reaction was
dependent on the yield of RNA for any given sample; samples with yields below 1000ng
either contained 250 ng (samples 11 and 42) or 500 ng (samples 16, 22, 28, and 35) of
RNA, while samples that had yields above 1000 ng contained 1000ng of RNA, in the
reactions. cDNA production occurred in the PCR cycler under the following conditions:
25°C for 10 minutes, 37°C for 120 minutes, and 85°C for 5 minutes. cDNA samples were
analyzed using a NanoDrop spectrophotometer (NanoDrop 2000; Thermo Scientific;
Rochester, NY).

Primer quality control: The zebrafish primers were tested for quality on AB wildtype
cDNA (Table 1). Primers were designed to target mRNA transcripts of both muscle and
nervous tissue specific genes observed in the proteomic studies (Integrated DNA
technologies, headquarters). 20 µL reactions were run using the protocol with the Taq
PCR Master Mix Kit (QIAGEN Inc; Valencia, CA). PCR ran under the following
conditions for 39 cycles: 94°C for denaturing, 55°C for annealing, and 72°C for
extension. PCR samples were then run in a 2% agarose gel for evaluation of target
amplification.

qPCR: 50 ng of each cDNA were tested in duplicate to SsoAdvanced Universal SYBR
Green Supermix (BioRad Laboratories; Hercules, CA) with actb1 zebrafish primers.
qPCR ran under the following conditions for 39 cycles: 95°C for denaturing, and 60°C
for annealing and extension. Samples were analyzed with CFX Manager™ Software
(BioRad Laboratories; Hercules, CA).
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Results
RNA:
To analyze the transcriptome of the zebrafish samples, RNA must first be
collected specifically mRNA. RNA extractions were performed on the individual spines
of the zebrafish, then analyzed the RNA samples concentrations and purity using
spectrophotometry. Before figuring out the optimal procedure, we tested co-precipitants
glycogen and linear acrylamide. RNA samples extracted with glycogen were ten times
higher than those extracted with linear acrylamide. The concentration of RNA samples
ranged from 26.3 to 725.2 ng/µL. The average concentration of RNA is 334.1 ng/µL
(Figure 1A). Purity was measured using the A260/A280 ratio. None of the RNA samples
have the optimal ratio of 2.0. Samples between 276 and 426 ng/µL have the highest
A260/A280 ratios. The average purity of the RNA samples 1.62 (Figure 2A).

cDNA:
To ensure that the spinal samples would last, cDNA was produced from RNA
through reverse transcription. DNA is a more stable molecule than RNA, so conversion
of RNA to cDNA wound ensure that the samples would be viable when we could analyze
them. After reverse transcription, the samples were analyzed using spectrophotometry.
The average concentration of the cDNA samples was 2758 ng/µL. There were fewer
cDNA samples with significantly lower yields than their counterparts, as there were
fewer cDNA samples with significantly lower yields than their counterparts, as there was
only one sample that was below 1500 ng/µL (54) and five samples that were above 4000
ng/µL (53, 59, 65, 66, and 72) (Figure 1B). The A260/A280 of the cDNA samples,
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measuring purity, are approximately 1.8 for samples between 1928 and 3200 ng/µL. The
A260/A280 of these samples range from 1.67 to 1.82, with an average of 1.77 (Figure 2B).

qPCR:
Before samples could go through transcriptome analysis, they must first be tested
to make sure they are compatible with the SYBR master mix that will be used in said
analysis. This was done by testing 50 ng of cDNA from each of all thirty-five samples
with the same primer pair, actb1, and checked for consistent amplification. However,
variation of the levels of actb1, or actin, transcripts were observed between samples. The
average relative fluorescent unit (RFU) measurement was 2025 RFU. Samples with the
G93R mutation had higher RFU measurements than their wildtype counterparts (Figure
3A). Samples exposed to 2.5 µg/L of BMAA had lower RFU measurements than other
samples (Figure 3B).
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Discussion
Overall, the results illustrated several important points about the protocols
involved collecting samples for transcriptome analysis. Even when RNA samples were
extracted with glycogen as the co-precipitant, the concentration of samples varied
significantly, with less than optimal purity. These samples, when converted to cDNA,
increased in yield and purity. When samples were tested for compatibility with the SYBR
master mix, it was found that there was variation in actb1 levels between different
samples.
Several modifications had to be made to the original RNA extraction procedure
to increase the RNA yield as well as the purity of each RNA samples. The modification
that increased the yield of RNA was changing the co-precipitant from linear acrylamide
to glycogen. The changes made to protocol to make the samples purer were doubling the
time samples were centrifuged, and increasing the temperature of centrifuging samples
from 4°C to room temperature.
. When testing RNA extraction methods using linear acrylamide, it was noticed
that the RNA yields were averaging less than 50 ng/µL, so less than half of the minimum
yield required to use in future experiments. We looked up some similar extraction
procedures that successfully used glycogen instead of linear acrylamide as the coprecipitant.29 From this, it was hypothesized that using glycogen as a co-precipitant
would increase the RNA yield more than linear acrylamide. When RNA from wildtype
AB zebrafish was extracted with both 250x linear acrylamide, and 1 mg/ mL glycogen,
the samples extracted with glycogen exhibited higher yields. However, a possible reason
why there might be a higher yield with glycogen than with linear acrylamide is because
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the glycogen is added in with the TRIzol reagent before the chloroform step. This is the
opposite of using linear acrylamide, as linear acrylamide is added after the chloroform in
procedures that use that co-precipitant. By providing the glycogen more time to contact
the RNA, it increased the odds of the glycogen pelleting the RNA.
Next, it was thought that the purity of RNA samples would increase if the
centrifuging stages in the extraction procedure were performed for double the time at
25°C than the time suggested at 4°C. This was from consultation with Dr. Roger Sher
[personal communication], which suggested that the salts from the TRIzol were
precipitating into the RNA pellet when centrifuging the samples at 4°C. At room
temperature, it was thought that these salts would not precipitate, thus increasing the
purity of the RNA samples. This was in an attempt to prevent the salts from the TRIzol
reagent from precipitating into the pellet, which had been previously seen to contaminate
the RNA samples. While samples were still not found to be at the optimal purity, they
were sufficiently purified for the RNA to be produced into cDNA for the purposes of
expression analysis.
With the thirty-five RNA samples extracted, samples varied in overall yield. This
is contradictory to how the procedure was predicted to work, as a similar amount of RNA
should come from similar sample sizes. The main source of error from the extraction
procedure is most likely human error. This is due to multiple people with different levels
of experience performing the procedure involved in the collection of RNA samples
(Figure 1A).
There is a noticeable trend that samples with relatively low or high RNA have
lower A260/A280 ratios than samples with more average concentrations (Figure 2A). While
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low A260/A230 ratios were also observed, they were expected to be low for two reasons;
glycogen was being used as the co-precipitant, and the main component of TRIzol is
phenol. Residual phenol and glycogen are both known to lower the purity of nucleic acid
samples, especially lowering A260/A230 ratios.30 Due to the very low A260/A230 ratios, and
the relatively normal A260/A280 ratios, the A260/A280 ratio was considered the more
accurate measurement of purity. There was consideration to precipitate RNA samples
with poorer purity and rewash samples, but this additional procedure would decrease the
yield enough that it would be insufficient for producing cDNA from.
The variation of RNA concentrations between the samples was a concern for the
next step of the procedure, cDNA production. According to the protocol that came with
the Applied Biosystems cDNA Reverse Transcription kit (Applied Biosystems; Carlsbad,
CA), 1 µg of RNA was required to produce cDNA. For samples with low yields, 250 ng
(11 and 42) or 500 ng (16, 22, 28, and 35) of RNA were used (Figure 1A). However, the
resulting cDNA concentrations from these samples were sufficient for future analysis,
even with smaller yields than other samples. All of the cDNA samples that were of a high
concentration (greater than 3000 ng/µL) came from samples in which 1 µg of the
sample’s RNA was added to the reaction mixture (10, 17,18, 23, 34, 40, 48, 53, 66, 67,
and 72) (Figure 1B). These results show that a substantial amount of cDNA can be
produced with a quarter of the RNA stated the protocol, but not necessarily an optimal
amount. This is good to know for producing cDNA samples from very small pieces of
tissue in the future. Overall, enough cDNA was produced to perform qPCR analysis on
all of the sample.
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The purity of the cDNA samples was more optimal than the purity of the RNA
samples. Unlike the RNA, the optimal A260/A280 ratio for cDNA is 1.8. Most of the cDNA
samples have an approximate ratio of 1.8. Samples with cDNA concentrations higher
than 3500 ng/µL are less pure, with A260/A280 ratios between 1.6 and 1.8 (Figure 2B).
These cDNA samples are more pure than the RNA counterparts because it is suspected
that there is less of the residual phenol in the samples. Not all of the RNA is necessary for
most of the cDNA samples, so when the small amount of RNA is transferred to the
reaction mixture, only some of the contaminants come with it. The small amount of
contaminant dilutes into the 20 µL reaction mixture, and thus has less of an effect on the
purity of the resulting cDNA sample.
Once all the samples were collected, it was hypothesized that the gene for actin
could be used as a housekeeping gene for qPCR quality control. This idea stems from the
fact that actin filaments comprise of globular actin, and these filaments are part of the
cytoskeletons on all cell types, not just neurons. While the research did suggest that
glycogen increased the RNA yield of samples, and purity did increase when the samples
were centrifuged at 25°C, the levels of actin transcripts varied among samples (lowest for
samples exposed to 2.5 µg/L BMAA.) Since this is a constitutive gene, it is expected that
all samples should have similar relative fluorescent unit (RFU) measurements, since the
same amount of cDNA was added into each reaction. As can be seen in the results, the
measurements vary greatly. The measurements ranged from 75 to 3655 RFU. To observe
whether these difference could be due to one of the experimental variables, the samples
were color coded by genotype and BMAA exposure. There were significant differences
between the RFUs of genotype groups, displaying greater RFU averages for transgenic
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samples than non-transgenic samples, and samples with the G93R mutation have higher
RFU’s than those without the mutation (Figure 3A). More analysis will have to go into
how a constitutive gene is influenced by the amount of wild type SOD1-wt transcript and
the G93R mutation, since these results are contradictory to what was expected. There is
also a significant decrease of actin transcript when samples were exposed to 2.5 ug/L of
BMAA as opposed to 0.0 ug/L and 5.0 ug/L (Figure 3B). This result is understandable,
because previous studies in this lab have shown that the length of motor neuron axons
decrease the most when zebrafish are exposed to a dose of 2.5 µg/L of BMAA. Actin is a
prominent cytoskeletal protein found in actin filaments, especially in the axon, so it
makes sense that there would be less actin transcripts in the neurons of fish exposed to
this dosage of BMAA.
For future directions, there are multiple methods of studying the cDNA samples
that we have collected. First, if possible, there should be an alternative housekeeping
gene found to be used as a control. This way, we can observe the levels of nonconstitutive genes in comparison. While qPCR analysis was attempted with gapdh
primers before actb1 primers were used, it was observed that the reverse primers showed
amplification in a negative control without cDNA added. The most likely possibility of
this observation is contamination. New primers can be designed and ordered for gapdh,
and tested again to observe their levels in these samples. After a second useful control
primer is found, the next step will be to test each cDNA sample with the ten primers
mentioned in table 1. This way, we can observe basic upregulation and downregulation
patterns of target neurological and muscle genes. These results would help scientists look
at genetic regulation when it comes to exposure of BMAA, the G93R mutation, the
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overexpression of the wildtype and SOD1 genes, and a combination of these factors.
Also, we can perform microarray analysis using twelve 96 well plates from Bar Harbor
Biotechnology containing 94 genes involved with neurotoxicity and neurodegeneration
(and two control genes). These plates have a primer pair for distinct neurological gene in
each well. Each plate would be used for a sample type with a genotype and an exposure
of BMAA. For example, one plate would have cDNA from a sample(s) from nontransgenic SOD-wt littermates exposed to 5.0 µg/L of BMAA during early development.
This way, we can get a comprehensive look at genetic regulation of neurological genes
depending on these conditions.

20

Conclusion
This research provides several conclusions that are useful for future research.
From modifying the procedure, it is demonstrated that not only using glycogen as a coprecipitant for extraction increases the RNA yield of a sample, but also that centrifuging
the samples at 25°C for double the recommended time increases the purity of the RNA
samples. These observations will be important for extracting RNA from nervous tissue in
the future. The data also verifies the short axons measured in Samantha Power’s work; a
correlation can be made between the fewer actin transcripts in the cell, and the shorter
length of the axons. This means that actb1 is not a good gene to analyze if looking for a
good housekeeping gene in the near future. It is also an indicator that the samples used in
this experiment are consistent with zebrafish with the same genotypes used in previous
experiments. Overall, the samples collected through this research are pure enough, and
are at a high enough concentration, that they can be used for future transcriptome
analysis, using microarrays to perform said analysis. The transcriptome analysis can then
be compared with the performed proteomics. This information will then contribute
toward the summation information toward how neurotoxins in the environment can
influence the development of ALS, and thus lead to possible treatments for the disease.
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actb1

aldoaq

chata

gapdh

myhb

myh2

spg20b

tpm1

tubla

vars

1

2

3

4

5

6

7

8

9

10

5’ – GGT AAC GTC ATC GAC CCT CT- 3’

5’- GGA GGA CAG GAG CCA ACA GT - 3’

5’ - GCC GTA GGA ACC TTG ACA TT- 3’

5’ - ACC TGA CCA TTT CCT ATG GC - 3’

5’- CAA CAA GAA GGC CAG TGA GA - 3’

5 ‘- CCA TGA TCA GTC AGG GTG AG - 3’

5’- GCT GGT ATT GCT CTC AAC GA - 3’

5’- ATT GCC AAG GAG CTG AAA CT - 3’

5’ - CAT CCT TGC TGC TGA TGA GT - 3’

5’- TCC TCC CAC CAT GAA GAT CA – 3’

Forward Primer Sequence

5’-GTC GGA TTT CTG TCC CTG TT -3’

5’-GAG CTT CTC TTC GAC GCT CT – 3’

5’- AGG GCA CCA TCA AAC CTA AG- 3’

5’- CCA GAC TAC TCC CAG CAG GT- 3’

5’-TCA AGG GTA CCC AGA AGA CC – 3’

5’- AAG CCC AGA ATA TCA ATG GC – 3’

5’- CTA CTC CTT GGA GGC CAT GT - 3’

5’- GAC TGG ACC ATA GCA GCA GA - 3’

5’- TAC AAC CTC CGG TTC TCC TC - 3’

5’ - CTT GCT GAT CCA CAT CTG CT - 3’

Reverse Primer Sequence

Table 1. Zebrafish primers that target muscle and nervous system related genes.

Gene
Target

Primer
Pair
Number
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Figure 1. The concentration (ng/µL) for A) RNA samples and B) cDNA products, varies
from sample to sample.
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Figure 2. A260/A280 ratios are dependent on the nucleic acid concentration. A) A260/A280
ratio dependent on RNA concentration (ng/µL). B) A260/A280 ratio dependent on cDNA
concentration (ng/µL).
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Figure 3. RFU measurements of actb1 transcripts are different depending on genotype
and BMAA concentration zebrafish were exposed to. A) RFU depending on genotype.
B) RFU depending on BMAA concentration.
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